Clinical Study on Huatuo Zaizao Pills for Post-stroke Treatment

The Effect of Huatuo Zaizao Pill on Neurological Function and Motor Recovery in Ischemic Stroke Patients During the Recovery Stage: a Open-labelled, Randomized Controlled Trial

The purpose of this study was to evaluate the improvement of limb motor function and nerve function of patients with HTZZ during stroke rehabilitation. A total of 80 subjects will be randomly assigned to Huatuo Zaizao pill group or the control group.

This is a prospective, randomized controlled clinical trial. Eighty patients with phlegm and blood stasis block syndrome of ischemic stroke were randomly assigned to Hua Hua reconstruction group or control group at a ratio of 1:1. The treatment period is 12 weeks. The purpose is to evaluate its efficacy and safety, provide an objective basis for precise treatment of traditional Chinese medicine, and improve clinical efficacy. The main result is the changes of MAS scores 12 weeks days after taking the drug. The secondary result is the change in NIHSS, Fugl-Meyer and BI.

Inclusion Criteria:

• 1.Aged between 35 and 75 years old
• 2.With a disease course between 2 weeks- 24weeks
• 3.Meeting the diagnostic criteria of ischemic stroke
• 4.Signed and dated written informed consent.
• 5.4≤NIHSS score≤22

Exclusion Criteria:

• 1.Unstable vital signs, or serious heart, liver, lung, kidney and other organ diseases
• 2.Exclude Transient Ischemic Attack(TIA)
• 3.Patients who are participating in clinical trials of other drugs within the past 1 month
• 4.Pregnant or breastfeeding women
• 5.Athletes, Epileptics, Allergic to this product